The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (ISDA) released several significant updates to the AASLD-IDSA HCV Guidance. The latest version has been modified to reflect important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance. In addition to updates to all the sections, the following new sections have been added to the Guidance:
View the updated guidance.
